Novo Nordisk’s stock tumbles as doubts persist about Ozempic maker’s strategy
The drugmaker, best known for developing weight-loss and diabetes drugs, failed to excite investors hoping for a turnaround.
Source：MarketWatch
友情提醒：請廣大讀者理性看待市場資訊，切實提高風險意識。站內所有內容僅系市場資訊或相關方觀點，不構成任何形式投資建議。